GV Investment Managers

GV Investment Managers is a private equity firm founded in 2000 and based in Stamford, Connecticut. The firm specializes in impact investing, private equity, and portfolio management services. It focuses on sectors such as life sciences, consumer products, enterprise solutions, cryptocurrency, climate technology, and frontier innovations. With Alphabet as its sole limited partner, GV Investment Managers primarily targets investments in North America and Europe. The firm collaborates with operating partners who assist startups in areas such as design, diversity and inclusion, talent acquisition, and engineering, while also facilitating connections with Google for technological support and expertise.

Brian Bendett

Partner

Brendan Bulik-Sullivan

General Partner

Terri Burns

Partner

Frederique Dame

Partner

Karim Faris

General Partner

Crystal Huang

Partner

Tom Hulme

General Partner and Head of Europe

John Lyman

Partner

Laura Melahn

Partner

Erik Nordlander

General Partner

David Reshef

Venture Partner

Ben Robbins

General Partner

Issi Rozen

Venture Partner

M.G. Siegler

General Partner

Andy Wheeler

General Partner

Krishna Yeshwant

Managing Partner

Sangeen Zeb

Partner

David Schenkein

General Partner

Past deals in Growth Stage

Omni

Series B in 2025
Omni is a multifaceted company based in San Francisco, California, that specializes in business intelligence, cybersecurity, and cloud engineering services. Its primary offering is a unique business intelligence platform that merges the reliability of a shared data model with the flexibility of SQL, allowing users to easily access, explore, and share curated data metrics. This platform is designed to streamline the data analytics process, enabling clients to focus on deriving meaningful insights without the complications often associated with data management. Additionally, Omni operates a rentals platform that connects local businesses with community members, providing access to a variety of rental items such as bikes, surfboards, and camping equipment. This initiative enhances community engagement by making diverse products readily available for short-term use.

Blockaid

Series B in 2025
Blockaid enable builders to protect users from fraud, phishing and hacks.

Vitara Biomedical

Series B in 2024
Vitara Biomedical develops a therapeutic platform to support premature infants. It offers natural physiological processes and hopes to transform neonatal care for newborns and their families into a lifetime of possibilities.

Metsera

Series B in 2024
Metsera is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for obesity and metabolic conditions. The company focuses on advancing a variety of oral and injectable treatment options, including incretin, non-incretin, and combination therapies. These treatments are designed to address multiple therapeutic targets, positioning Metsera to meet the evolving demands of the weight loss treatment landscape. Additionally, Metsera integrates proprietary health technology tools to provide personalized care, enhancing the effectiveness of its therapeutic offerings.

Infinitus Systems

Series C in 2024
Infinitus Systems is an AI healthcare company focused on automating phone-based processes to enhance efficiency within the healthcare ecosystem. By streamlining tedious and time-consuming communication tasks, Infinitus aims to improve access to therapy, adherence, and affordability for patients. The company's innovative tool allows users to submit call requests easily, track updates, and receive notifications upon task completion. Infinitus Systems has raised $51.4 million in funding from prominent investors, including Kleiner Perkins, Coatue, and Google Ventures. Through its automation solutions, the company seeks to reduce the complexity and costs associated with back-office administration in the healthcare sector.

Scope3

Series B in 2024
Scope3 operates a supply chain emissions data platform that provides accurate and comprehensive emissions data to assist companies in integrating sustainability into their business decisions. The company develops models that outline the core inputs and outputs for products and services within the supply chain, enabling organizations to design more sustainable systems. Additionally, Scope3 prepares monthly sustainability reports that offer updated emissions data, allowing businesses to swiftly adapt to external changes and recognize their efforts in reducing carbon footprints.

Harvey

Series C in 2024
Harvey is an artificial intelligence technology service provider for knowledge workers. It uses AI to answer legal questions and lands cash from OpenAI. The product provides lawyers with a natural language interface for their existing legal workflow. It offers a unified and intuitive interface for all legal workflows, allowing lawyers to describe tasks in plain English instead of using a suite of complex and specialized tools for niche tasks. Harvey was founded in 2022 and is based in Washington, DC.

Hebbia

Series B in 2024
Hebbia Inc. is a technology company that specializes in developing AI productivity tools tailored for knowledge workers. Established in 2020 and headquartered in West Hollywood, California, Hebbia offers a unique platform designed to facilitate complex task management by transforming prompts into actionable processes completed by AI agents. The platform is utilized by professionals in finance, law, government, and pharmaceuticals, enabling them to handle extensive workflows involving millions of documents. Unlike many AI systems that operate as a black box, Hebbia's technology is transparent, allowing users to verify and collaborate effectively with the AI. It efficiently ingests both structured and unstructured data from various sources, retrieves relevant information upon request, and presents answers in a user-friendly, spreadsheet-like format, thereby supporting comprehensive workflow automation.

Santa Ana Bio

Series B in 2024
Santa Ana Bio is a biotechnology company focused on developing precision therapies for autoimmune and inflammatory diseases. By utilizing advanced technologies such as deep cell profiling, single-cell genomics, and multi-omics platforms, the company designs targeted biologics that aim to provide effective and personalized treatment options. Through its innovative approach, Santa Ana Bio seeks to enhance patient outcomes and improve quality of life for those affected by autoimmune conditions.

StrongDM

Series C in 2024
StrongDM helps organizations manage and secure access to critical infrastructure by using a zero-trust approach. The platform provides users with controlled access to databases, servers, and applications, while also giving administrators clear visibility and audit trails.

Midi Health

Series B in 2024
Midi Health is a virtual care clinic dedicated to addressing the health needs of women, particularly during menopause and related conditions. The clinic specializes in treating issues such as depression, gynecological cancer, and menstrual problems through a clinical platform that delivers personalized care protocols. These protocols are administered by clinicians who are trained in female midlife health. Midi Health enhances its services by utilizing specialized at-home labs, providing prescription medications, supplements, and lifestyle coaching. This comprehensive approach aims to empower women to manage the challenges they face during critical stages of their lives and careers.

Ripcord

Venture Round in 2024
Ripcord, Inc. is a robotic digitization company founded in 2014 and headquartered in Los Angeles, California. The company specializes in creating a platform for paperless document management, utilizing advanced technologies such as artificial intelligence, machine learning, and vision-guided robotics. Their primary product, Canopy, employs automation software to capture, enrich, and organize essential content, effectively creating a digital twin of information. By integrating sensors and software automation, Ripcord enables enterprises to enhance their business processes, improving speed, quality, and accuracy in managing important documents. The company, originally known as Ripcord Digital, Inc., rebranded in June 2017 to reflect its focus on innovative digitization solutions.

Alethea

Series B in 2024
Alethea is a technology company helping the Fortune 500, private companies and nonprofits protect themselves from harms stemming from disinformation. Leveraging its multi-channel machine learning platform, Artemis, Alethea detects disinformation narratives across the internet, enabling customers to proactively defend against this pervasive threat. With Artemis-powered early detection, Alethea customers can protect their reputations, key assets, physical safety and market value. The company was founded in 2019 and is woman owned.

Oula Health

Series B in 2024
Oula Health, Inc. specializes in maternity care services, offering both in-clinic and home-based prenatal care. Founded in 2019 and located in Brooklyn, New York, Oula aims to transform the maternity care experience by integrating obstetrics and midwifery. The company focuses on providing a personalized and evidence-based approach to pregnancy, combining modern medical practices with a compassionate understanding of human needs. Through its innovative maternity center, Oula sets a new standard for pregnancy care that emphasizes both medical expertise and personal connection.

Accent Therapeutics

Series C in 2024
Accent Therapeutics is a biopharmaceutical company developing oncology-focused, small molecule therapies in the emerging field of epitranscriptomics. This field of biology encompasses post-transcriptional chemical modifications of RNA that provide cells with a unique mechanism for regulating proteins critical for cellular growth and differentiation. By targeting cancer-linked RNA-modifying proteins (RMPs) with precision therapies, they aim to translate extraordinary science into life-changing therapies for patients.

Comanche Biopharma

Series B in 2024
Comanche Biopharma is a biopharmaceutical company focused on developing an investigational small interfering RNA (siRNA) medicine aimed at treating preterm preeclampsia. The company is committed to ensuring that all women and their babies have access to safe and effective therapies for life-threatening complications during pregnancy. Comanche Biopharma's mission emphasizes the importance of evidence-based and affordable solutions, enabling women to receive cost-effective treatments that address the root causes of preeclampsia.

Lightmatter

Series C in 2023
Lightmatter specializes in developing photonic chips that leverage light for data processing and communication, significantly enhancing the speed and efficiency of artificial intelligence computations. By utilizing integrated optical technology, the company designs processors that accelerate key operations in neural networks through programmable photonic elements, which are fabricated alongside traditional transistors. This innovative approach allows for improved performance in applications such as image recognition and natural language processing while maintaining low power consumption. Lightmatter's technology primarily serves sectors including artificial intelligence, cloud computing, and telecommunications, positioning the company as a leader in light-based computing solutions.

Seismic Therapeutic

Series B in 2023
Seismic Therapeutic is a biotechnology company focused on accelerating immunology drug development through the integration of machine learning in the biologics discovery process. Its IMPACT™ platform addresses key challenges in biologics discovery by combining structural biology, protein engineering, and translational immunology. This innovative approach aims to create optimized therapies more efficiently, ultimately benefiting patients with autoimmune diseases and disorders linked to adaptive immune system dysregulation. With a robust pipeline of biologics, Seismic Therapeutic is committed to enhancing the speed and efficacy of drug development in the field of immunology.

Scope3

Series B in 2023
Scope3 operates a supply chain emissions data platform that provides accurate and comprehensive emissions data to assist companies in integrating sustainability into their business decisions. The company develops models that outline the core inputs and outputs for products and services within the supply chain, enabling organizations to design more sustainable systems. Additionally, Scope3 prepares monthly sustainability reports that offer updated emissions data, allowing businesses to swiftly adapt to external changes and recognize their efforts in reducing carbon footprints.

ROME Therapeutics

Series B in 2023
ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Established in 2019, the company utilizes the repeatome—a previously overlooked segment of genetic material—to create novel treatment options. By identifying multiple drug targets and advancing several discovery programs, ROME Therapeutics aims to tap into this unexplored area of biology. The organization has assembled a team of experts in oncology, immunology, virology, and machine learning to lead its research and development efforts, which are designed to provide healthcare professionals with effective new treatments for patients suffering from these conditions.

Modular

Series B in 2023
Modular is an AI software developer platform that unifies the development and deployment of AI for everyone. The product breakthroughs will be powered by production quality infrastructure that brings together compilers and runtimes, is designed for heterogeneous computing, edge to datacenter distribution, and is focused on usability. Unifying software and hardware with a "just works" approach will save developers enormous time and increase their velocity.

deepset

Series B in 2023
Deepset is a company specializing in natural language processing (NLP) solutions, focusing on leveraging the latest advancements in machine learning to create real-world applications. It is known for developing the Haystack open-source framework, which facilitates the deployment of NLP tasks, and for offering deepset Cloud, a platform designed for enterprise AI teams. Since its inception in 2018, deepset has supported numerous AI teams globally by providing reliable, open-source technology and tailored solutions. The company's software emphasizes the use of transfer learning to enhance model performance while minimizing the amount of training data required, thereby enabling users to unlock value from diverse text sources effectively.

Typeface

Series B in 2023
Typeface is a generative AI application for creating enterprise content. Enterprises can now create on-brand content faster combining content velocity with brand personalization and control. It offers self-service content development solutions for the entire lifecycle, allowing every employee to create captivating content with ease, speed, and brand authenticity.

Nothing

Series C in 2023
Nothing is a consumer electronics company that designs and manufactures smartphones, earbuds, and other connected devices. It aims to remove barriers between people and technology by focusing on product integration and user experience. The company offers mobile devices and personalized noise-cancellation earbuds featuring wireless charging, water resistance, and dual connectivity. Through its innovative approach, Nothing seeks to create a seamless digital ecosystem that combines hardware and software, providing customers with reliable and durable technology at affordable prices.

Redpanda Data

Series C in 2023
Redpanda Data is a company that provides a modern streaming data platform designed to handle large data streams effectively. Its platform allows users to record both real-time and historical enterprise data, making it a valuable tool for organizations that require efficient data management. Redpanda's architecture features a compatible application programming interface and is deployable as a single binary, which simplifies the deployment process. Additionally, it includes a built-in schema registry and operates without external dependencies, enhancing performance and reliability for developers. This combination of features enables enterprises to maintain their software stacks while improving data processing capabilities.

Warp

Series B in 2023
Warp is a developer of a Rust-based coding terminal designed to make teams productive at coding and application development. The company's software divides the terminal output of a command-line interface into a sequence of commands rather than a single buffer. It replaces the character buffer with a full-fledged text editor which enables software developers to navigate, copy, save and share units of work and transform the terminal from an inherently single-user utility into a modern collaborative application where sessions, blocks, and environments are all persistent, searchable and shared by link.

Synthesia

Series C in 2023
Synthesia Ltd. is a London-based company that specializes in an artificial intelligence-driven video production platform. Founded in 2017, the company offers a service that transforms text into professional-quality videos featuring customizable avatars and voiceovers in over 140 languages. Its innovative video synthesis technology allows users to create high-end videos for various applications, including personalized advertising, corporate communications, e-learning, and marketing. By synchronizing lip movements with new dialogue tracks, the platform facilitates the translation of video content into different languages, thereby enhancing distribution channels. Users can quickly create, edit, and share studio-quality videos directly in their browser, utilizing fully cloneable AI video templates to streamline production and meet diverse content needs.

Lightmatter

Series C in 2023
Lightmatter specializes in developing photonic chips that leverage light for data processing and communication, significantly enhancing the speed and efficiency of artificial intelligence computations. By utilizing integrated optical technology, the company designs processors that accelerate key operations in neural networks through programmable photonic elements, which are fabricated alongside traditional transistors. This innovative approach allows for improved performance in applications such as image recognition and natural language processing while maintaining low power consumption. Lightmatter's technology primarily serves sectors including artificial intelligence, cloud computing, and telecommunications, positioning the company as a leader in light-based computing solutions.

AMP

Series C in 2023
AMP is an AI technology company that modernizes recycling infrastructure through smart sortation solutions. The company focuses on maximizing resource recovery while minimizing labor costs for waste management operations. With numerous deployments globally, AMP aims to transform the economics of recycling.

Clever Care Health Plan

Series C in 2023
Clever Care Health Plan, Inc. is a healthcare insurance provider that specializes in Medicare Advantage plans, integrating the principles of Eastern and Western medicine. Founded in 2018 and headquartered in Westminster, California, with an additional office in Arcadia, the company offers a range of culturally sensitive healthcare solutions. Its plans include access to services such as acupuncture, herbal remedies, tai chi, and cupping, aimed at enhancing both physical and mental well-being. Clever Care connects its members with diverse networks of hospitals and healthcare providers who are attuned to their cultural needs and language preferences. The company distributes its products through brokers and sales agents, ensuring that Medicare beneficiaries receive the support and services they require.

Chroma Medicine

Series B in 2023
Chroma Medicine is a genomic medicine company based in Cambridge, Massachusetts, founded in 2021. The company focuses on epigenetic editing, aiming to revolutionize the treatment of genetically driven diseases. By utilizing epigenetics, which is nature's inherent mechanism for regulating genes, Chroma Medicine develops programmable epigenetic editors that target specific genes and control chromatin conformation. This innovative approach combines a DNA binding domain with epigenetic effector domains, providing medical practitioners with a new class of therapeutics that offers enhanced control over gene expression.

Aera Therapeutics

Series B in 2023
Aera Therapeutics is a biotechnology company focused on enhancing the delivery of genetic medicines through its proprietary protein nanoparticle (PNP) platform. This innovative platform utilizes endogenous human proteins to create capsid-like structures that can effectively package and transfer nucleic acid cargo. By addressing the limitations of current delivery technologies, Aera aims to extend the application of genetic medicines across various tissues and disease areas, ultimately benefiting a wider patient population. In addition to its PNP platform, Aera has developed a therapeutic enzyme platform that features novel, compact, and programmable gene-editing enzymes, further advancing its mission to transform the field of genetic medicine.

Mill

Venture Round in 2023
Mill is a company focused on addressing food waste, a significant environmental challenge. It offers innovative kitchen bins that dry, shrink, and eliminate odors from leftover food, transforming waste into a compost-like material. These digitally connected bins can be rented, allowing users to efficiently manage their kitchen waste overnight. Additionally, Mill facilitates the shipping of the processed material to facilities that convert it into animal feed, thereby promoting a sustainable waste management system. Through its products and services, Mill aims to contribute to a healthier environment by providing practical solutions for reducing food waste at home.

Chronosphere

Venture Round in 2023
Chronosphere, Inc. is a technology company that specializes in developing an open-source metrics data platform known as M3. Founded in 2019 and headquartered in New York, the company has additional offices in Seattle, Vilnius, and Warsaw. Chronosphere's platform provides comprehensive monitoring solutions for infrastructure, applications, and business metrics, enabling organizations to manage the complexities of cloud-native environments. By offering tools that help DevOps teams quickly identify and resolve issues across various layers of the technology stack, Chronosphere enhances operational reliability and supports data-driven decision-making. The platform is utilized by prominent brands to improve developer productivity, control costs, and enhance customer satisfaction.

Carrick Therapeutics

Series C in 2022
Carrick Therapeutics, Ltd., established in 2015 and headquartered in Dublin, Ireland, focuses on developing innovative cancer therapeutics aimed at transforming cancer treatment. The company targets molecular pathways associated with aggressive and resistant forms of cancer, employing advanced mechanisms to improve treatment outcomes. By enabling the detection of predictive biomarkers, Carrick Therapeutics facilitates the initiation of targeted therapies at early stages, ultimately striving to enhance the lives of cancer patients.

Pangea

Series B in 2022
Pangea is a developer of security APIs that offers a comprehensive portfolio of security services tailored for application builders. The company provides a single platform that simplifies the integration of security into cloud and mobile applications. Pangea's services are designed to be globally accessible while maintaining regional intelligence, making them suitable for diverse markets. Available on major cloud platforms such as AWS and GCP, Pangea enables clients—including app developers, SaaS providers, and security operations teams—to efficiently create secure and compliant user experiences. The company aims to make security accessible to all developers, eliminating the need for extensive security expertise.

Dandelion Energy

Series B in 2022
Dandelion Energy, Inc., founded in 2017 and based in Palo Alto, California, specializes in providing affordable geothermal heating and cooling installations. The company has developed a home geothermal system that replaces traditional air conditioning and heating equipment with an efficient heat pump and safe underground pipes. This system harnesses thermal energy from the earth to regulate indoor temperatures and produce hot water, allowing homeowners to transition from conventional heating fuels to a more sustainable geothermal solution. Dandelion Energy aims to make renewable energy accessible and cost-effective for residential customers.

AMP

Series C in 2022
AMP is an AI technology company that modernizes recycling infrastructure through smart sortation solutions. The company focuses on maximizing resource recovery while minimizing labor costs for waste management operations. With numerous deployments globally, AMP aims to transform the economics of recycling.

Landis

Series B in 2022
Landis is an online real estate platform founded in 2018 and headquartered in New York, NY, that focuses on helping renters become homeowners. The company allows clients to choose their dream home, rent it, and purchase it within the first twelve months. In addition to facilitating this transition, Landis provides tools and incentives designed to assist clients in improving their credit scores and accumulating down payment savings. With a commitment to transparency and simplicity, Landis aims to create a seamless process for renters to transition to homeownership. The company also specializes in commercial real estate technology and residential offerings.

Flatfile

Series B in 2022
Flatfile Inc. is a company that specializes in data onboarding solutions, enabling developers to efficiently validate, map, and import CSV data from various web applications. Founded in 2018 and based in Denver, Colorado, Flatfile offers a platform that integrates seamlessly with software applications, allowing users to upload data through formats such as CSV, XLS, or TSV. Its key products include Portal, which provides an import button embedded via a JavaScript snippet, and Concierge, which creates secure collaborative workspaces for organizations to manage complex data ingestion challenges. The platform is designed to enhance developer productivity, reduce costs, and improve data quality by learning to identify and clean incoming data over time. Numerous companies, including AstraZeneca and Square, utilize Flatfile’s API-first platform to streamline their data import processes.

SpinLaunch

Series B in 2022
SpinLaunch is a stealth space catapult startup that aims to creates a much cheaper and sustainable way to get things like satellites from earth into space without chemical propellant. SpinLaunch plans to use a centrifuge spinning at an incredible rate inside a vacuum that reduces friction. All that momentum is then harnessed to catapult a payload into space at speeds one source said could be around 3000 miles per hour. With enough momentum, objects could be flung into space on their own. Alternatively, the catapult could provide some of the power needed with cargo being equipped with supplemental rockets necessary to leave the earth’s atmosphere.

Sardine

Series B in 2022
Sardine is a financial technology company that specializes in providing a risk and fraud infrastructure tailored for the online economy. It has developed a device intelligence platform that leverages artificial intelligence and advanced risk engine software. This platform enhances fraud detection while minimizing sign-up friction by analyzing multiple real-time data points, including device information, browser details, and behavioral biometrics. By integrating this technology, Sardine enables businesses to establish a robust risk and fraud management framework, ultimately reducing costs within the fintech ecosystem.

Vitara Biomedical

Series B in 2022
Vitara Biomedical develops a therapeutic platform to support premature infants. It offers natural physiological processes and hopes to transform neonatal care for newborns and their families into a lifetime of possibilities.

Kindbody

Venture Round in 2022
Kindbody is a fertility clinic network and family-building benefits provider that offers a comprehensive range of services aimed at supporting individuals and couples in their journey to parenthood. The company's offerings include fertility assessments, preservation, genetic testing, in vitro fertilization (IVF), as well as donor, surrogacy, and adoption services. Employers collaborate with Kindbody to provide their employees with essential financial, medical, and emotional support throughout the family-building process. Kindbody serves over 100 employers, impacting more than 2.4 million lives, while also delivering fertility care through its network of signature clinics, mobile clinics, and partner clinics across the country. The organization emphasizes improving access to holistic health and fertility services for women at affordable rates, utilizing modern technology to enhance the patient experience.

Merlin Labs

Series B in 2022
Merlin Labs is an innovative company focused on creating autonomous flight technology for advanced air travel, primarily utilizing fixed-wing aircraft. Founded in 2018 and headquartered in Boston, Massachusetts, the company develops a sophisticated aircraft autonomy system that employs artificial intelligence and machine learning, akin to the technology used in driverless cars. This system aims to facilitate the pilotless transportation of goods and eventually people, establishing a new infrastructure for aerial mobility.

Medallion

Series C in 2022
Medallion is a company that offers a network management platform tailored for the healthcare industry, focusing on simplifying the complex processes of licensing, credentialing, and payer enrollment. Founded in 2020 by Derek Lo and based in San Francisco, California, Medallion's all-in-one platform addresses the logistical challenges that healthcare providers and telemedicine companies face, enabling them to minimize time spent on administrative tasks. Key features of the platform include facilities for new licensing and renewals, primary source verification, continuing medical education tracking, and document management. By streamlining these processes, Medallion allows healthcare professionals to concentrate more on patient care rather than paperwork.

Courier

Series B in 2022
Courier provides a notification management platform that allows developers to effectively route user notifications across various communication channels, such as email, SMS, and messaging apps. By utilizing an API, the platform intelligently determines the optimal channel for delivering messages based on user engagement and online status. This capability enables businesses to craft a single message that can be reused across multiple channels or customized for specific platforms, ensuring timely and relevant communication with users, business partners, and external stakeholders. With a commitment to customer success, Courier has evolved alongside technological advancements while maintaining stable management practices and long-term relationships with its clients.

Wonder

Series B in 2022
Wonder is a company that operates in two distinct sectors: gaming and food delivery. In the gaming industry, Wonder develops an all-in-one platform specifically for Android mobile devices, enabling users to play, stream, and share games seamlessly across different devices, thus enhancing the overall gaming experience. In the food delivery sector, Wonder runs truck-based restaurants that allow consumers to order food via a mobile app. These trucks are dispatched to locations near users’ homes, where they prepare meals on-site to ensure freshness and quality in deliveries. This dual focus on technology and culinary services positions Wonder uniquely in the market, catering to diverse consumer needs.

Nava

Series B in 2022
Nava is a health insurance brokerage based in New York, dedicated to providing high-quality and affordable healthcare solutions for employers and their employees. The company offers a range of services, including healthcare tools, year-round employee advocacy, and ongoing plan measurement. These services are designed to help clients select and manage their healthcare plans effectively, ensuring that they can offer necessary benefits while also reducing overall costs. Through its innovative approach, Nava aims to enhance the healthcare experience for both employers and employees.

FarmWise

Series B in 2022
FarmWise provides technology-based services that allow farmers to streamline farm operations and increase food production efficiency. It offers a productive mechanical weeding implement for vegetable crops, along with its exceptional training and support program. The company was founded in 2016 and is based in San Francisco, California.

Gametime

Venture Round in 2022
Gametime is a mobile platform that specializes in selling last-minute tickets for a variety of live events, including sports, concerts, and theater, across the United States and Canada. The service simplifies the ticket purchasing process by curating a selection of the best available options from over 10,000 seats, allowing clients to choose from 50 top values. Each ticket option is accompanied by a high-resolution panoramic photo, providing users with a preview of the view from their chosen section. The platform features interactive seat maps that allow for easy comparison of prices and locations, enhancing the customer experience. Tickets are conveniently delivered directly to the user's phone, facilitating instant access to entertainment.

Invetx

Series B in 2022
Invetx, Inc. is a biotechnology company focused on developing protein-based therapeutics for animal health care and veterinary medicine. Based in Boston, Massachusetts, Invetx's team comprises veterinary scientists and clinicians dedicated to discovering and creating biotherapeutics for both pets and farm animals. The company aims to enhance health outcomes in the animal health industry by leveraging biopharma technologies, supported by a network of experts in animal and human health. Through its innovative platform, Invetx is committed to advancing a portfolio of therapies and technologies designed to improve animal care and well-being.

Aspen Neuroscience

Series B in 2022
Aspen Neuroscience, Inc. is a biotechnology company focused on developing induced pluripotent stem cells (iPSCs) to create patient-specific therapies for neurological conditions, particularly Parkinson's disease. Founded in 2018 and based in San Diego, California, the company is advancing its pipeline of products, which includes ANPD001, an autologous neuron replacement therapy for sporadic Parkinson's disease, and ANPD002, a gene-edited autologous neuron replacement therapy targeting familial forms of the disease. Aspen Neuroscience employs innovative genomic approaches in conjunction with stem cell biology to address diseases with significant unmet medical needs, aiming to provide restorative cell therapies that can modify the progression of Parkinson's disease and potentially extend to other affected organs.

OMass Therapeutics

Series B in 2022
OMass Therapeutics Limited is a biotechnology company based in Oxford, United Kingdom, that specializes in drug discovery through structural mass spectrometry. Founded in 2016, the company employs innovative mass spectrometry platforms to develop therapeutics aimed at difficult disease targets. By providing access to native mass spectrometry, OMass Therapeutics enables clients in the biotechnology and pharmaceutical sectors to study complex protein assemblies and their interactions with other biological molecules. This approach allows clients to address challenging drug targets and biotherapeutics more effectively, fostering a collaborative environment for advancing novel medicines.

Obsidian Security

Series C in 2022
Obsidian Security, Inc. develops cloud infrastructure and data center security solutions, focusing on cybersecurity and artificial intelligence to address cyber threats in hybrid-cloud environments. The company provides a platform that enables threat detection, breach remediation, and security hardening specifically for business-critical software as a service (SaaS) applications. By delivering cloud detection and response capabilities, Obsidian Security aims to enhance the security posture of enterprises. Founded in 2017 and headquartered in Newport Beach, California, the company is dedicated to creating a comprehensive understanding of interconnected applications to ensure their safety and security.

Brightline

Series C in 2022
Brightline, Inc. is a provider of pediatric behavioral health care services, established in 2019 and headquartered in Palo Alto, California. The company offers a range of services including behavior therapy, psychiatry and medication support, speech-language therapy, and occupational therapy. Brightline operates as a technology-enabled behavioral health home, utilizing innovative technology and virtual services to deliver integrated care. Its collaborative care team focuses on supporting children throughout their developmental stages and addressing the needs of their families. Brightline was previously known as Emilio Health, Inc. and rebranded in May 2020.

Digits

Series C in 2022
Digits is a fintech company building tools for businesses and finance professionals by leveraging its proprietary Living Model technology. The company was founded by Wayne Chang and Jeff Seibert in 2018 and is headquartered in San Francisco, California, United States.

LifeMine Therapeutics

Series C in 2022
LifeMine Therapeutics, Inc. is a biotechnology company focused on discovering new drug modalities from eukaryotic microbes, particularly fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, the company employs an integrated platform that combines genomics, artificial intelligence, and synthetic biology. This innovative Avatar-Rx platform utilizes high-throughput microbiology, data science, machine learning, genome engineering, and automation to explore the fungal biosphere for novel genetically encoded molecules with specific biological functions. By integrating chemoinformatic-assisted drug optimization and advanced chemical synthesis with biotransformation, LifeMine Therapeutics aims to advance a pipeline of new medicines into development.

Spotlight Therapeutics

Series B in 2022
Spotlight Therapeutics, Inc. specializes in the development of gene editing therapeutics designed to target specific cell populations directly within the body. Established in 2017 and based in Hayward, California, the company leverages a biotechnology platform that utilizes CRISPR nuclease effectors for in vivo gene editing. Its innovative approach aims to create next-generation programmable nucleases that enhance treatment options for a variety of conditions. Spotlight Therapeutics is focused on multiple therapeutic areas, including immuno-oncology, ophthalmology, and hematology, and is developing programs to address previously undruggable intracellular gene targets as well as specific monogenic disease targets related to the eye. This targeted gene editing strategy seeks to overcome the challenges associated with traditional delivery methods, thereby providing healthcare providers with improved tools for patient treatment.

Nothing

Series B in 2022
Nothing is a consumer electronics company that designs and manufactures smartphones, earbuds, and other connected devices. It aims to remove barriers between people and technology by focusing on product integration and user experience. The company offers mobile devices and personalized noise-cancellation earbuds featuring wireless charging, water resistance, and dual connectivity. Through its innovative approach, Nothing seeks to create a seamless digital ecosystem that combines hardware and software, providing customers with reliable and durable technology at affordable prices.

Redpanda Data

Series B in 2022
Redpanda Data is a company that provides a modern streaming data platform designed to handle large data streams effectively. Its platform allows users to record both real-time and historical enterprise data, making it a valuable tool for organizations that require efficient data management. Redpanda's architecture features a compatible application programming interface and is deployable as a single binary, which simplifies the deployment process. Additionally, it includes a built-in schema registry and operates without external dependencies, enhancing performance and reliability for developers. This combination of features enables enterprises to maintain their software stacks while improving data processing capabilities.

RightHand Robotics

Series C in 2022
RightHand Robotics, Inc. specializes in the manufacturing of robotic order-picking systems designed to enhance supply chain logistics and order fulfillment across various industries, including e-commerce, food handling, and flexible manufacturing. Founded in 2015, the company is headquartered in Cambridge, Massachusetts, with an additional office in Frankfurt, Germany. RightHand Robotics offers innovative solutions like the ReFlex SF, which features a 3D-printed palm equipped with advanced servos and compliant fingers, and the ReFlex TakkTile, a tactile sensor that aids in gentle object handling. Their technology enables robots to automatically grasp a wide range of items from bins and cases without the need for extensive data entry or parameter tuning, making their systems cost-effective and adaptable to changing business needs.

Genesis Global

Series C in 2022
Genesis Global enables financial markets organizations to innovate at speed through a software application development platform, prepackaged solutions and deep expertise in capital markets and financial services. In supercharging developers to rapidly deliver high-performance, resilient and secure applications, Genesis replaces the buy vs. build challenge with a buy-to-build solution. The Genesis platform is designed with flexibility and performance at its core, providing developers with the frameworks, integrations and components required to automate manual workflows, enhance legacy systems and build entirely new applications. Featuring a resilient, real-time service-oriented architecture, Genesis excels across the performance envelope of low-latency, high-throughput and high-scalability, powering mission-critical applications at the world’s leading financial institutions. Strategically backed by Bank of America, BNY Mellon and Citi, Genesis Global has offices in Miami, New York, Charlotte, London, Leeds, São Paulo, Dublin and Bengaluru.

Homebound

Series C in 2022
Homebound is a custom homebuilder that makes building the perfect home simple, transparent and human. Born out of the 2017 Northern California wildfires, Homebound was created by a local team of construction, real estate, design and technology experts who set out to create a better homebuilding solution for friends, family and neighbors affected. Homebound is the first homebuilder to manage the entire building process for homeowners and support them every step of the way — from insurance negotiation and architecture all the way to permitting, construction and move-in. Through easy-to-use technology and a network of vetted building experts, Homebound is simplifying the rebuilding process and alleviating the stress, complexity and uncertainty homeowners face after a natural disaster.

Ventus Therapeutics

Series C in 2022
Ventus Therapeutics is a biopharmaceutical company focused on discovering and developing novel small molecule medicines aimed at treating autoimmune diseases, inflammatory diseases, and cancer by targeting the innate immune system. The company employs a structural immunology platform that provides deep insights into the mechanisms and molecular structures involved in immune responses. This platform integrates proprietary protein engineering capabilities with advanced rational and structure-based drug design tools, allowing for precise targeting of the innate immune system. Ventus is actively building a pipeline of drug programs that address critical targets within this system, particularly proteins involved in inflammasome and nucleic acid-sensing signaling pathways, thereby enabling the treatment of both acute and chronic inflammatory and immune-related conditions.

Pecan

Series C in 2022
Pecan operates a predictive analytics platform that empowers businesses to forecast critical outcomes effectively. It utilizes a low-code interface that simplifies the predictive modeling process, allowing companies to generate accurate predictions without needing in-house data scientists or engineers. Pecan automates data preparation and feature engineering, enabling users, particularly SQL-trained business intelligence analysts, to create tailored predictive models quickly. The platform supports various industries, including fintech, insurance, retail, and consumer services, by providing pre-built models and templates that align with specific business objectives. This capability allows organizations to enhance customer lifetime value, retention, conversion rates, and demand forecasting. Pecan's solutions have a significant financial impact, influencing billions of dollars in revenue across various sectors.

Censys

Series B in 2022
Censys, Inc. specializes in internet scanning and asset identification solutions, offering a platform that enables organizations to gain a real-time view of global networks and devices. Founded in 2017 and based in Ann Arbor, Michigan, Censys provides tools for attack surface management, allowing users to discover unknown assets, monitor remote workforces, and identify threat actors. Its internet intelligence platform is designed for threat hunting and exposure management, creating a comprehensive dataset that enhances visibility into vulnerabilities and internet-exposed infrastructure. This enables businesses to efficiently locate and manage the devices, networks, and infrastructure that are critical to their operations.

Mill

Series B in 2022
Mill is a company focused on addressing food waste, a significant environmental challenge. It offers innovative kitchen bins that dry, shrink, and eliminate odors from leftover food, transforming waste into a compost-like material. These digitally connected bins can be rented, allowing users to efficiently manage their kitchen waste overnight. Additionally, Mill facilitates the shipping of the processed material to facilities that convert it into animal feed, thereby promoting a sustainable waste management system. Through its products and services, Mill aims to contribute to a healthier environment by providing practical solutions for reducing food waste at home.

Found

Series B in 2021
Found is dedicated to improving people’s overall wellbeing by making evidence-based weight loss accessible and affordable. The company was founded in 2019 and is headquartered in San Francisco, California, United States.

Synthesia

Series B in 2021
Synthesia Ltd. is a London-based company that specializes in an artificial intelligence-driven video production platform. Founded in 2017, the company offers a service that transforms text into professional-quality videos featuring customizable avatars and voiceovers in over 140 languages. Its innovative video synthesis technology allows users to create high-end videos for various applications, including personalized advertising, corporate communications, e-learning, and marketing. By synchronizing lip movements with new dialogue tracks, the platform facilitates the translation of video content into different languages, thereby enhancing distribution channels. Users can quickly create, edit, and share studio-quality videos directly in their browser, utilizing fully cloneable AI video templates to streamline production and meet diverse content needs.

Universe

Series B in 2021
Universe is a mobile application that enables users to create websites, online shops, and portfolios. The platform provides essential tools, including a payment block for processing transactions and an order management system to streamline financial operations. By facilitating the building of digital presence and supporting e-commerce activities, Universe aims to simplify the online selling experience for individuals and businesses alike.

Upbound

Series B in 2021
Upbound, Inc. is a technology company that specializes in multi-cloud solutions, enabling organizations to manage and optimize their operations across various cloud environments as a cohesive unit. Founded in 2017 and based in Seattle, Washington, Upbound's platform is powered by Crossplane, allowing platform engineers to create, deploy, and operate internal developer platforms with enhanced control and self-service capabilities. The company provides tools for automation, cost optimization, capacity overflow, failover, and policy enforcement, helping organizations to streamline their multi-cloud deployments. Additionally, Upbound offers Universal Crossplane (UXP), which includes security features, support, and a range of official providers, further enhancing the flexibility and efficiency of cloud management for its users.

mabl

Series C in 2021
Mabl Inc. is an intelligent test automation company based in Boston, Massachusetts, founded in 2016. It offers an automated testing service that leverages machine learning to identify regressions and automatically fix broken tests. The platform provides scriptless testing and integrates seamlessly into the continuous integration and continuous deployment (CI/CD) development lifecycle, allowing software teams to create and maintain reliable, auto-healing tests. By streamlining the testing process, Mabl enables organizations to enhance the speed and quality of their software releases, facilitating faster delivery of high-quality applications while helping developers and testers address bugs before they reach production.

Ankyra

Series B in 2021
Ankyra is a biotechnology company focused on developing anchored immunotherapy for cancer treatment. The company addresses the limitations of traditional cytokine therapies, which are often restricted due to widespread immune activation and associated toxicity. Ankyra's innovative approach involves the use of its Anchored Immunotherapy Platform to create ANK-101, a stable complex of a modified IL-12 cytokine and aluminum hydroxide, an FDA-approved adjuvant. This combination allows for targeted intratumoral delivery, enhancing the localized retention and activity of IL-12 while reducing systemic side effects. By optimizing the therapeutic potential of anchored immunotherapy, Ankyra aims to improve treatment outcomes for cancer patients, offering a safer and more effective alternative to conventional therapies.

Infinitus Systems

Series B in 2021
Infinitus Systems is an AI healthcare company focused on automating phone-based processes to enhance efficiency within the healthcare ecosystem. By streamlining tedious and time-consuming communication tasks, Infinitus aims to improve access to therapy, adherence, and affordability for patients. The company's innovative tool allows users to submit call requests easily, track updates, and receive notifications upon task completion. Infinitus Systems has raised $51.4 million in funding from prominent investors, including Kleiner Perkins, Coatue, and Google Ventures. Through its automation solutions, the company seeks to reduce the complexity and costs associated with back-office administration in the healthcare sector.

Yellowbrick Data

Series C in 2021
Yellowbrick Data was founded in 2014 by experts in database and flash memory technologies to simplify data warehousing. They wanted to solve the challenges of high availability, running complex mixed workloads, support for ad-hoc SQL, computing correct answers on any schema, massive scalability and supporting large numbers of concurrent users. Yellowbrick Data empowers companies to make faster decisions with all of their data. Built for enterprises and the hybrid cloud, the Yellowbrick Data Warehouse deploys powerful analytics anywhere, with best-in-class economics.

Multiverse

Series C in 2021
Multiverse is an EdTech startup focused on providing an alternative to traditional university education through career-oriented apprenticeships. By matching young talent with professional services and digital roles, Multiverse aims to deliver relevant skills and applied learning experiences. The platform not only equips individuals with necessary competencies but also fosters the development of social capital and professional networks, empowering them to shape their own career paths. This approach offers a viable alternative to conventional university routes and standard corporate training programs, catering to the evolving needs of the workforce.

StrongDM

Series B in 2021
StrongDM helps organizations manage and secure access to critical infrastructure by using a zero-trust approach. The platform provides users with controlled access to databases, servers, and applications, while also giving administrators clear visibility and audit trails.

Genome Medical

Series C in 2021
Genome Medical, Inc. is a company based in South San Francisco, California, that specializes in genetic consultation and medical consulting services. Established in 2016, it operates a platform that connects individuals and healthcare providers to genetic specialists through its Genome Care Delivery technology. The company offers expert virtual genetic care across various clinical areas, including cancer, cardiovascular health, reproductive health, pediatrics, and pharmacy. By providing genetic assessments and personalized clinical action plans, Genome Medical enables patients to understand their genetic risks, make informed treatment decisions, and enhance overall health outcomes. The company aims to facilitate the integration of genomic medicine into everyday healthcare, assisting both patients and practitioners in navigating the complexities of genetic testing and its implications for disease diagnosis and management.

Ultromics

Series B in 2021
They are building world-class diagnostic aids to help cardiologists — powered by artificial intelligence. To date, they have developed the world’s most accurate echocardiography software to improve the diagnosis of coronary heart disease by more than 90%.

Snorkel AI

Series C in 2021
Snorkel AI, Inc. is a company that develops a comprehensive machine-learning platform designed to facilitate the creation, management, and monitoring of AI applications. Its primary offering, Snorkel Flow, allows users to programmatically label and augment training data, manage and integrate various datasets, and deploy machine learning models, while also providing tools for data analysis and monitoring. The platform is particularly effective in extracting structured information from complex documents and forms, as well as ranking content based on relevance. Founded in 2016 and based in Palo Alto, California, Snorkel AI serves a diverse range of industries, including finance, government, telecommunications, insurance, healthcare, and e-commerce. The technology was developed at Stanford AI Lab and employs innovative methods such as weak supervision to enhance data preparation, thereby streamlining the AI development process for enterprises.

Sonoma Biotherapeutics

Series B in 2021
Sonoma Biotherapeutics is a company invloved the development of adoptive Treg therapies cell for autoimmune and degenerative diseases. Using next generation genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies.

Neuralink

Series C in 2021
Neuralink is focused on developing implantable brain-machine interfaces aimed at assisting individuals with paralysis and addressing neurological conditions. The company is dedicated to creating high-bandwidth devices that not only facilitate treatment and diagnosis but also have the potential to enhance cognitive abilities. By innovating in this field, Neuralink seeks to enable medical professionals to effectively manage serious brain diseases while expanding the capabilities of individuals within the community.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.